ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics reported solid Q3 results, reflecting continued demand for its immunoglobulin portfolio. Revenue reached $134.224 million, up from $119.839 million a year ago, with net income of $36.428 million and diluted EPS of $0.15. Gross profit was $75.626 million, and income from operations rose to $51.012 million.
On the balance sheet, cash and equivalents were $61.385 million and total assets were $568.687 million as of September 30, 2025. Long-term debt stood at $70.084 million. The company refinanced with a new JPMorgan facility, drawing a $75 million term loan and establishing a $225 million revolver; the term loan rate was approximately 6.75% at quarter-end.
ADMA authorized a share repurchase program of up to $500.0 million and repurchased 1.329 million shares for $23.188 million year-to-date. The FDA approved an ASCENIV/BIVIGAM process PAS in April 2025 that has started to increase bulk yields; the company states it believes this should drive revenue and earnings accretion beginning in Q4 2025. ADMA also acquired Boca Raton real estate for $12.6 million to support expanded operations.
ADMA Biologics (ADMA) furnished a press release announcing financial results for the three months ended September 30, 2025, and a business update. The release is attached as Exhibit 99.1 to an 8‑K dated November 5, 2025. The information under Item 2.02 is expressly stated as furnished, not filed, and is not subject to Section 18 liabilities nor incorporated into other filings unless specifically referenced. ADMA’s common stock trades on the Nasdaq Global Market.
ADMA Biologics (ADMA) President & CEO and Director Adam S. Grossman reported Form 4 transactions on 10/24/2025. He exercised 15,000 stock options at $5.40 (Code M) and sold 15,000 and 6,000 common shares at $16 (Code S) under a Rule 10b5-1 trading plan.
After these trades, he held 2,019,850 shares directly. He also reported indirect holdings of 1,143,426 shares via Areth, LLC and 580,957 shares via Hariden, LLC, as disclosed in the footnotes.
Adam S. Grossman, President & CEO and director of ADMA BIOLOGICS (ADMA), reported multiple transactions on 09/15/2025 under a previously disclosed Rule 10b5-1 plan. He exercised a stock option to acquire 15,000 shares at an exercise price of $5.40 and sold a total of 21,000 shares (15,000 and 6,000) at $16.13. After these transactions he directly owned 2,025,850 shares and indirectly controlled an additional 1,724,383 shares through Areth, LLC and Hariden, LLC. The option exercised was originally granted on 02/26/2024 and vests through 02/26/2028. The reporting person also holds unvested RSUs totaling 1,033,966 across grants from 2022–2025 that will settle into common stock upon vesting.
Adam S. Grossman, President and CEO and a director of ADMA Biologics, reported multiple transactions on 08/15/2025 under a Rule 10b5-1 plan. He exercised an option covering 15,000 shares with an exercise/conversion price of $5.40 and simultaneously sold 21,000 shares (15,000 and 6,000) at $16.88 per share. Following these transactions the reporting person directly beneficially owns 2,031,850 shares. He also has indirect interests of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes disclose large unvested RSU balances totaling 1,033,166 shares across multiple grants and an outstanding option schedule tied to a 2024 grant.
State Street Corporation reported beneficial ownership of 12,078,505 shares of ADMA Biologics common stock, equal to 5.1% of the outstanding class. The filing discloses shared voting power over 11,187,440 shares and shared dispositive power over 12,078,505 shares, while reporting no sole voting or sole dispositive power. The holder states the position is maintained in the ordinary course of business and not held to influence control of the issuer. Several State Street affiliates are identified as the acquiring subsidiaries and are classified as investment advisers.
ADMA Biologics (ADMA) Form 4 highlights: Chief Operating Officer & SVP Compliance Kaitlin M. Kestenberg-Messina exercised 2,500 employee stock options on 07/30/2025 at an exercise price of $8.98 (code “M”).
To satisfy the exercise price and mandatory tax withholding, 1,208 shares were withheld by the issuer (code “F”), so no open-market sale occurred. Net 1,292 shares were added to the insider’s direct holdings.
Post-transaction ownership: 488,690 directly held common shares, consisting of 194,166 fully vested shares and 294,524 unvested RSUs from grants made between 2022-2025 that will vest quarterly over four-year schedules.
The 07/30/2015 option grant is now fully exercised and no derivative securities from this grant remain outstanding.
No other transactions, purchases, or sales were reported. Filing was signed 08/01/2025.
ADMA Biologics COO & SVP, Compliance Kaitlin M. Kestenberg-Messina filed a Form 4 for an automatic share withholding event on 07/24/2025. Transaction code F shows 3,027 common shares were surrendered to the company at $17.31 per share to satisfy payroll-tax obligations triggered by the vesting of restricted stock units (RSUs); no shares were sold on the open market.
Post-transaction, the executive beneficially owns 487,398 ADMA shares, comprised of 192,874 fully vested shares and 294,524 unvested RSUs that vest quarterly through 2029, contingent on continued service.
- The filing is a routine tax-settlement and does not reflect a discretionary reduction in ownership.
- Share count outstanding is modestly reduced, but insider economic exposure is unchanged.